154 related articles for article (PubMed ID: 37741510)
1. Functional determination of emicizumab in presence of factor VIII activity.
Hamedani NS; Donners AAMT; van Luin M; Gasper S; Rühl H; Klein C; Albert T; El Amrani M; Pötzsch B; Oldenburg J; Müller J
J Thromb Haemost; 2023 Dec; 21(12):3490-3500. PubMed ID: 37741510
[TBL] [Abstract][Full Text] [Related]
2. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.
Bowyer A; Kitchen S; Maclean R
Haemophilia; 2020 May; 26(3):536-542. PubMed ID: 32249990
[TBL] [Abstract][Full Text] [Related]
3. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies.
Nogami K; Soeda T; Matsumoto T; Kawabe Y; Kitazawa T; Shima M
J Thromb Haemost; 2018 Jul; 16(7):1383-1390. PubMed ID: 29734520
[TBL] [Abstract][Full Text] [Related]
4. Emicizumab, the factor VIII mimetic bi-specific monoclonal antibody and its measurement in plasma.
Tripodi A; Chantarangkul V; Novembrino C; Scalambrino E; Boscolo-Anzoletti M; Clerici M; Rossi F; Peyvandi F
Clin Chem Lab Med; 2020 Sep; 59(2):365-371. PubMed ID: 32892172
[TBL] [Abstract][Full Text] [Related]
5. Chromogenic Factor VIII Assay for Patients with Hemophilia A and on Emicizumab Therapy.
Yacoub OA; Duncan EM
Methods Mol Biol; 2023; 2663():597-610. PubMed ID: 37204739
[TBL] [Abstract][Full Text] [Related]
6. In vitro validation of chromogenic substrate assay for evaluation of surrogate FVIII-activity of emicizumab.
Yamaguchi T; Shinozawa K; Nagatoishi S; Mitsuhashi A; Bingo M; Inaba H; Amano K; Tsumoto K; Kinai E
Thromb Res; 2023 Feb; 222():131-139. PubMed ID: 36657269
[TBL] [Abstract][Full Text] [Related]
7. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X.
Ogiwara K; Nogami K; Matsumoto N; Noguchi-Sasaki M; Hirata M; Soeda T; Shima M
Int J Hematol; 2020 Nov; 112(5):621-630. PubMed ID: 32748217
[TBL] [Abstract][Full Text] [Related]
8. Anti-idiotype monoclonal antibodies against emicizumab enable accurate procoagulant and anticoagulant assays, irrespective of the test base, in the presence of emicizumab.
Ogiwara K; Furukawa S; Shinohara S; Tabuchi Y; Arai N; Noguchi-Sasaki M; Soeda T; Shima M; Nogami K
Haemophilia; 2023 Jan; 29(1):329-335. PubMed ID: 36137299
[TBL] [Abstract][Full Text] [Related]
9. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab.
Nogami K; Matsumoto T; Tabuchi Y; Soeda T; Arai N; Kitazawa T; Shima M
J Thromb Haemost; 2018 Jun; 16(6):1078-1088. PubMed ID: 29645406
[TBL] [Abstract][Full Text] [Related]
10. Effects of Emicizumab on APTT, FVIII assays and FVIII Inhibitor assays using different reagents: Results of a UK NEQAS proficiency testing exercise.
Lowe A; Kitchen S; Jennings I; Kitchen DP; Woods TAL; Walker ID
Haemophilia; 2020 Nov; 26(6):1087-1091. PubMed ID: 33094895
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.
Schmitt C; Adamkewicz JI; Xu J; Petry C; Catalani O; Young G; Negrier C; Callaghan MU; Levy GG
Thromb Haemost; 2021 Mar; 121(3):351-360. PubMed ID: 33086400
[TBL] [Abstract][Full Text] [Related]
12. The combination of emicizumab and recombinant factor VIII in plasma: Which assays can we use for accurate measurement?
Bowyer AE; Maclean RM; Kitchen S
Int J Lab Hematol; 2023 Jun; 45(3):368-376. PubMed ID: 36710421
[TBL] [Abstract][Full Text] [Related]
13. Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A.
Kaneda M; Kawasaki R; Matsumoto N; Abe H; Tashiro Y; Inokuchi Y; Yasuno H; Sasaki-Noguchi M; Soeda T; Yoshimura Y; Oka T
J Thromb Haemost; 2021 Dec; 19(12):2938-2946. PubMed ID: 34418287
[TBL] [Abstract][Full Text] [Related]
14. The effect of a next generation factor VIII mimetic bispecific antibody (Mim8) on assays of factor VIII activity and thrombin generation.
Bowyer AE; Kitchen S; Ezban M
J Thromb Haemost; 2023 Mar; 21(3):480-487. PubMed ID: 36696203
[TBL] [Abstract][Full Text] [Related]
15. Effect of emicizumab-neutralizing antibodies on activated partial thromboplastin time-based clotting time test results in patients treated with emicizumab.
Novembrino C; Boscolo-Anzoletti M; Galbiati E; Shinohara S; Peyvandi F
Res Pract Thromb Haemost; 2023 Nov; 7(8):102260. PubMed ID: 38193066
[TBL] [Abstract][Full Text] [Related]
16. A hemophilia A mouse model for the in vivo assessment of emicizumab function.
Ferrière S; Peyron I; Christophe OD; Kawecki C; Casari C; Muczynski V; Nathwani A; Kauskot A; Lenting PJ; Denis CV
Blood; 2020 Aug; 136(6):740-748. PubMed ID: 32369559
[TBL] [Abstract][Full Text] [Related]
17. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF
J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050
[No Abstract] [Full Text] [Related]
18. Emicizumab for the treatment of acquired hemophilia A.
Knoebl P; Thaler J; Jilma P; Quehenberger P; Gleixner K; Sperr WR
Blood; 2021 Jan; 137(3):410-419. PubMed ID: 32766881
[TBL] [Abstract][Full Text] [Related]
19. Optimization and evaluation of a two-stage chromogenic assay procedure for measurement of emicizumab plasma levels.
Hamedani NS; Oldenburg J; Pötzsch B; Müller J
PLoS One; 2022; 17(7):e0271330. PubMed ID: 35834493
[TBL] [Abstract][Full Text] [Related]
20. Early real-world experience with emicizumab and concomitant factor VIII replacement products in adult males with Hemophilia A without inhibitors.
Cafuir L; Estrin A; Chen E; Hinds D; Prince P; Thorburn J; Mead H; Kempton CL
J Med Econ; 2022; 25(1):984-992. PubMed ID: 35848992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]